What is the 13F Pro Quality Score for RLYB?

13F Pro ranks Rallybio Corp (RLYB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RLYB's current score at https://13fpro.ai/company/RLYB (free sign-up required for the full ranking).

Which hedge funds own the most RLYB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RLYB include ADAR1 Capital Management,, FMR, VIKING GLOBAL INVESTORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RLYB as soon as new 13F filings post.

Where does 13F Pro source RLYB data?

All Rallybio Corp fundamentals and ownership data come directly from SEC EDGAR. Rallybio Corp files with the SEC under CIK 1739410. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RLYB in?

Rallybio Corp (RLYB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RLYB research updated on 13F Pro?

RLYB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rallybio Corp(RLYB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1739410 RLYB stock profile & AI dashboard →

13F Pro Quality Score

70.3/100

Rank #224 of 2,962 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RLYB Scores 70/100

exact factor attribution · 2026-09-11

RLYB's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.3 pts

92th pct

Profitability

+7.5 pts

100th pct

Free cash flow

+7.5 pts

100th pct

Capital efficiency

+5.0 pts

100th pct

Earnings growth

+2.2 pts

95th pct

Earnings quality

+1.7 pts

67th pct

Institutional flow

-2.3 pts

4th pct

Shareholder dilution

-2.4 pts

3th pct

Scale

-7.2 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RLYB Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Rallybio Corp (RLYB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RLYB at 70.3/100 on a 32-signal composite quality model, placing it at rank #224 of 2,962 stocks — the top 10% of the AI-ranked universe. Top institutional holders of RLYB by reported 13-F value include ADAR1 Capital Management, FMR, VIKING GLOBAL INVESTORS, based on the most recent SEC filings. RLYB trades on the Nasdaq exchange and files with the SEC under CIK 1739410. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLYB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rallybio Corp directly from SEC EDGAR. Rallybio Corp's 13F Pro composite quality score has ranged between 27 and 70 since 2026, currently 70.3 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Rallybio Corp

Quirks, history, and lore behind RLYB — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Connecticut.
2
The Numbers
Generates minimal revenue as it has no approved products yet — it runs on cash reserves and the hope that its pipeline pays off someday.
3
The History
Founded around 2017 and went public in the early 2020s, part of a wave of biotech startups betting on rare and severe diseases that larger pharma had long ignored.
4
The Secret
Its scientific focus is on hematology and maternal-fetal medicine — conditions so rare that most people have never heard of the diseases it's trying to treat.
5
The Lore
Its lead program targets ANCA-associated vasculitis and other conditions where the body's own immune system becomes the villain — a niche but life-threatening battleground.
6
The Giveaway
The ticker spells out the company's whole attitude: rally the biotech troops — it's Rallybio, the New Haven underdog swinging for rare-disease glory.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$0.00

Net Income

Q2 2026

$43.7M

ROIC

Q2 2026

-23.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+34.9% YoY

$858.0KFY 2025

FY22 —FY23 —FY24 $636.0KFY25 $858.0K

Net Income

+84.5% YoY

$-9.0MFY 2025

FY22 $-66.7MFY23 $-74.6MFY24 $-57.8MFY25 $-9.0M

Operating Income

+45.3% YoY

$-33.1MFY 2025

FY22 $-67.9MFY23 $-78.9MFY24 $-60.5MFY25 $-33.1M

EPS (Diluted)

+85.0% YoY

$-1.59FY 2025

FY22 $-2.09FY23 $-1.84FY24 $-10.61FY25 $-1.59

Total Assets

-8.6% YoY

$62.3MFY 2025

FY22 $180.4MFY23 $115.6MFY24 $68.1MFY25 $62.3M

Op. Cash Flow

+39.5% YoY

$-29.8MFY 2025

FY22 $-57.3MFY23 $-60.3MFY24 $-49.3MFY25 $-29.8M

Free Cash Flow

—FY 2025

FY22 $-57.3MFY23 $-60.3MFY24 $-49.3MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$858.0K +34.9%	$636.0K	—	—	—	—
Net Income	$-9.0M +84.5%	$-57.8M +22.5%	$-74.6M -11.9%	$-66.7M -41.8%	$-47.0M -77.8%	$-26.4M
Operating Income	$-33.1M +45.3%	$-60.5M +23.4%	$-78.9M -16.3%	$-67.9M -48.7%	$-45.6M -80.4%	$-25.3M
EPS (Diluted)	$-1.59 +85.0%	$-10.61 -476.6%	$-1.84 +12.0%	$-2.09 -13.6%	$-1.84	—
Total Assets	$62.3M -8.6%	$68.1M -41.1%	$115.6M -35.9%	$180.4M -1.0%	$182.2M +28.4%	$141.9M
Operating Cash Flow	$-29.8M +39.5%	$-49.3M +18.2%	$-60.3M -5.2%	$-57.3M -25.8%	$-45.5M -106.6%	$-22.0M
Free Cash Flow	—	$-49.3M +18.2%	$-60.3M -5.1%	$-57.3M -25.0%	$-45.9M -106.8%	$-22.2M

Get alerted when RLYB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rallybio Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RLYB

ADAR1 Capital Management, LLC
$14.8M926,352 sh
FMR LLC
$12.7M794,720 sh
VIKING GLOBAL INVESTORS LP
$8.4M524,347 sh
TPG GP A, LLC
$6.1M378,551 sh
Pivotal bioVenture Partners Investment Advisor LLC
$4.8M300,579 sh
RENAISSANCE TECHNOLOGIES LLC
$3.2M199,907 sh
Nantahala Capital Management, LLC
$3.0M188,422 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.8M172,497 sh
Almitas Capital LLC
$1.9M120,682 sh
Rangeley Capital, LLC
$1.7M104,850 sh

Fund	Value	Shares
ADAR1 Capital Management, LLC	$14.8M	926,352
FMR LLC	$12.7M	794,720
VIKING GLOBAL INVESTORS LP	$8.4M	524,347
TPG GP A, LLC	$6.1M	378,551
Pivotal bioVenture Partners Investment Advisor LLC	$4.8M	300,579
RENAISSANCE TECHNOLOGIES LLC	$3.2M	199,907
Nantahala Capital Management, LLC	$3.0M	188,422
VANGUARD CAPITAL MANAGEMENT LLC	$2.8M	172,497
Almitas Capital LLC	$1.9M	120,682
Rangeley Capital, LLC	$1.7M	104,850

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RLYB on your watchlist

Track score changes the day Rallybio Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RLYB a good stock to buy?

13F Pro's AI-powered analysis of Rallybio Corp (RLYB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RLYB are available on the RLYB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RLYB is classified as a small company.

Which hedge funds own RLYB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RLYB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rallybio Corp's investment landscape.